What's Your Diagnosis - Continuing Medical Education Credit
CMP Healthcare Media, Cliggott Publishing Group
330 Boston Post Road
PO Box 4027
Darien, CT 06820
Contact Information
We would like to hear your comments regarding this or other activities provided by Beam Institute. In addition, suggestions for future activities are welcome.
Contact us at:
Director of Continuing Education
Beam Institute
11 West 19th Street, 3rd Floor
New York, NY 10011-4280
Phone: 888-618-5781
Fax: 212-600-3050
E-mail: beaminstitute@cmp.com
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.